Canada's Aurinia Pharmaceuticals, formerly called Isotechnika, is shaking up its executive team and laying off staffers. The biotech says that Richard Glickman is now the acting CEO, replacing Robert Foster, who will take the CSO's job. About a third of the company's staff is being axed while it reduces the size of its offices by half. Release